Using Serum NGAL to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases
Author Information
Author(s): Leelawat Kawin, Narong Siriluck, Wannaprasert Jerasak, Leelawat Surang
Primary Institution: Rajavithi Hospital
Hypothesis
Can serum NGAL levels effectively distinguish cholangiocarcinoma from benign biliary tract diseases?
Conclusion
Serum NGAL and CA19-9 levels are significantly elevated in cholangiocarcinoma patients, making them potential biomarkers for diagnosis.
Supporting Evidence
- Serum CA19-9 and NGAL levels were significantly higher in cholangiocarcinoma patients compared to benign biliary tract disease patients.
- The AUC for CA19-9 was 0.81 and for NGAL was 0.79, indicating good diagnostic accuracy.
- The combination of CA19-9 and NGAL showed a sensitivity of 90% for detecting cholangiocarcinoma.
Takeaway
Doctors can use blood tests for NGAL and CA19-9 to help tell if someone has a serious liver cancer called cholangiocarcinoma or a less serious condition.
Methodology
The study used a prospective-specimen-collection, retrospective-blinded-evaluation design with 50 cholangiocarcinoma and 50 benign biliary tract disease cases.
Potential Biases
The study design aimed to avoid selection bias by collecting specimens before diagnosis.
Limitations
The study had a small number of early-stage cholangiocarcinoma cases and was conducted in a referral center with a high prevalence of cholangiocarcinoma.
Participant Demographics
The study included 221 obstructive jaundice patients, with 50 cholangiocarcinoma and 50 benign biliary tract disease cases selected.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 0.725–0.899
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website